U.S. markets closed
  • S&P Futures

    4,130.75
    -2.00 (-0.05%)
     
  • Dow Futures

    33,530.00
    -40.00 (-0.12%)
     
  • Nasdaq Futures

    13,967.50
    -8.25 (-0.06%)
     
  • Russell 2000 Futures

    2,222.90
    -2.00 (-0.09%)
     
  • Crude Oil

    60.51
    +0.33 (+0.55%)
     
  • Gold

    1,746.20
    -1.40 (-0.08%)
     
  • Silver

    25.38
    -0.05 (-0.18%)
     
  • EUR/USD

    1.1960
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.6230
    -0.0520 (-3.10%)
     
  • Vix

    16.65
    -0.26 (-1.54%)
     
  • GBP/USD

    1.3760
    +0.0008 (+0.06%)
     
  • USD/JPY

    108.8650
    -0.1830 (-0.17%)
     
  • BTC-USD

    63,352.86
    +3,348.19 (+5.58%)
     
  • CMC Crypto 200

    1,358.10
    +64.10 (+4.95%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,635.52
    -116.09 (-0.39%)
     

Biogen profit drops 22 pct due to Tecfidera-related costs

Jan 26 (Reuters) - Biogen Inc reported a near 22 percent fall in fourth-quarter income, hurt by higher costs related to its top-selling multiple sclerosis drug, Tecfidera.

The company said net income attributable fell to $649.2 million, or $2.99 per share, in the quarter ended Dec. 31 from $831.6 million, or $3.77 per share, a year earlier.

Biogen, which is set to spin off its hemophilia business in February, said total revenue inched up to $2.87 billion from $2.84 billion.

(Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)